Funding for this research was provided by:
Received: 8 June 2020
Accepted: 11 December 2020
First Online: 12 January 2021
Ethics approval and consent to participate
: This study was a post-hoc analysis of data collected in the MT-04 trial. The relevant independent ethics committee and institutional review board approved the trial protocol and amendments, and the trial followed the principles of the Helsinki Declaration.
: Not applicable.
: AB and SN report personal fees from ALK, during the conduct of the study. EH and SB are employees at ALK-Abelló A/S. JCV is an employee of the Universitäesmedizin Rostock, Germany and has lectured for and received honoraria from: ALK-Abello, Allergopharma, AstraZeneca, Avontec, Bayer, Bencard, Bionorica, Boehringer-Ingelheim, Cipla, Chiesi, Essex/Schering-Plough, GSK, Janssen-Cilag, Leti, MEDA, Merck/MSD, Mundipharma, Novartis, Nycomed/Altana, Pfizer, Revotar, Sandoz-Hexal, Stallergens, TEVA, UCB/Schwarz-Pharma, Zydus/Cadila and possibly others and has participated in Advisory Boards of ALK-Abello, Allergopharma, Avontec, Boehringer-Ingelheim, Cipla, Chiesi, Essex/Schering-Plough, GSK, Janssen-Cilag, Leti, MEDA, Merck/MSD, Mundipharma, Novartis, Paul-Ehrlich-Institute, Regeneron, Revotar, Roche, Sanofi-Aventis, Sandoz-Hexal, TEVA, UCB/Schwarz-Pharma and possibly others and has received funding for research from Deutsche Forschungsgemeinschaft, Land Mecklenburg-Vorpommern, GSK, MSD.